Table 3 Most frequent toxicities of any grade experienced by patients on this phase II study of erlotinib
From: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
All toxicities | n (%) patients | n (%) cycles |
|---|---|---|
Rash/desquamation | 34 (90) | 88 (79) |
Lymphopenia | 33 (87) | 81 (72) |
Diarrhoea | 23 (61) | 69 (62) |
Hyperglycaemia | 23 (61) | 50 (45) |
Fatigue/Lethargy | 24 (63) | 63 (56) |
Haemoglobin | 30 (79) | 78 (70) |
Alkaline phosphatase | 24 (63) | 52 (46) |
